Furthermore, AFP-negative tumors account for up to 30–40% of pathologically diagnosed HCC patients, which significantly hinders the application of AFP in the diagnosis and prognosis of HCC [10–12]. The gene discussed is AFP; the disease is hepatocellular carcinoma.